The Valley Desk

ArticleJournal of medical economicsPublished

Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

Institution
Merck & Co.

Publication record

Type
Article
Venue
Journal of medical economics
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Chemotherapy, Adjuvant; Markov Chains; Quality-Adjusted Life Years; Middle Aged; Cost-Benefit Analysis; Canada; Antibodies, Monoclonal, Humanized
PubMed ID
40654114
Added to directory
Source checked

Report a correction or request removal